Kidney Failure, Chronic Clinical Trial
Official title:
Almond Milk With Vitamin D: Impact on Vitamin D Status
Verified date | June 2024 |
Source | University of Florida |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overall goal is to enhance vitamin D status in a safe and effective manner. A 3-week randomized comparator-controlled trial among a cohort of adults with CKD (stages 3-5) (n=24) will test the main objective: Evaluate the bioefficacy of D3 in micro- and nanoparticles (4000IUs) in almond milk with the sub-objective of: Explore the effect of D3 in micro- and nanoparticles (4000IUs) in almond milk on inflammation markers CRP, TNF-α and IL-6.
Status | Completed |
Enrollment | 21 |
Est. completion date | November 18, 2023 |
Est. primary completion date | November 18, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - adults who have been diagnosed with CKD - have no GI disorders or GI disturbances - age 18 years or older - no food allergies or dietary restrictions - all with no contraindications to consuming anything by mouth as per their physician Exclusion Criteria: - no diagnosis of CKD - GI disorders - gastrointestinal disturbances - under 18 years old - food allergies to almonds - Dietary restrictions as medically indicated - trouble chewing/swallowing as confirmed by physician |
Country | Name | City | State |
---|---|---|---|
United States | University of Florida | Gainesville | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Florida |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Vitamin D | baseline to end line in the concentration of serum 25(OH)D3 between and within the control and intervention groups. | 21 days | |
Secondary | Calcium | baseline to end line in the concentration of serum calcium between and within the control and intervention groups. | 21 days | |
Secondary | PTH | baseline to end line in the concentration of serum PTH between and within the control and intervention groups. | 21 days | |
Secondary | parent vitamin D | baseline to end line in the concentration of serum parent vitamin D between and within the control and intervention groups. | 21 days | |
Secondary | IL-6 | baseline to end line in the concentration of serum IL-6 between and within the control and intervention groups. | 21 days | |
Secondary | C-reactive protein | baseline to end line in the concentration of C-reactive protein between and within the control and intervention groups. | 21 days | |
Secondary | TNF-alpha | baseline to end line in the concentration of serum TNF-alpha between and within the control and intervention groups. | 21 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03246984 -
VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ
|
N/A | |
Completed |
NCT02922361 -
Spending and Outcomes for Complex Medicare Advantage Patients
|
||
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Completed |
NCT01930396 -
Use of Tinzaparin for Anticoagulation in Hemodialysis
|
Phase 4 | |
Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
Completed |
NCT01922843 -
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
|
Phase 2 | |
Not yet recruiting |
NCT01674660 -
Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients
|
N/A | |
Not yet recruiting |
NCT01157260 -
The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT01209403 -
Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT00753116 -
Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension
|
Phase 1 | |
Recruiting |
NCT00532688 -
N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
|
Phase 2/Phase 3 | |
Completed |
NCT00528788 -
How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
|
Phase 4 | |
Completed |
NCT00534144 -
Comparison Between Effects of Two Iron Preparations on Protein in the Urine
|
Phase 1 | |
Completed |
NCT00226902 -
Vascular Reactivity in Kidney Disease Patients
|
N/A | |
Completed |
NCT00382044 -
Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients
|
N/A | |
Recruiting |
NCT00235287 -
Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00224081 -
DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)
|
Phase 4 | |
Completed |
NCT00071214 -
Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis
|
Phase 3 | |
Completed |
NCT00049907 -
Cardiac and Renal Disease Study (CARDS)
|
N/A | |
Completed |
NCT00006297 -
Risk Factors for CV Disease in a Dialysis Cohort
|
N/A |